Histone deacetylase (HDAC) inhibitors (PXDLOL) for the treatment of cancer alone or in combination with chemotherapeutic agent
Details for Australian Patent Application No. 2006313517 (hide)
International Classifications
Event Publications
15 May 2008 PCT application entered the National Phase
PCT publication WO2007/054719 Priority application(s): WO2007/054719
5 June 2008 Corrigenda
PCT applications that have entered the National Phase - Name Index Under the name TopoTarget UK Limited and Curagen Corporation, Application No. 2006313517, Under (71), correct the name to TopoTarget UK Limited and CuraGen Corporation.
31 March 2011 Assignment before Grant
CuraGen Corporation; TopoTarget UK Limited The application has been assigned to TopoTarget UK Limited
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2006313518-Reprogramming and genetic modification of cells
2006313509-Device for strapping packages with strap material
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser